Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2012 1
2013 1
2016 2
2017 1
2018 1
2019 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Clinical feasibility of a wearable, conformable sensor patch to monitor motor symptoms in Parkinson's disease.
Boroojerdi B, Ghaffari R, Mahadevan N, Markowitz M, Melton K, Morey B, Otoul C, Patel S, Phillips J, Sen-Gupta E, Stumpp O, Tatla D, Terricabras D, Claes K, Wright JA Jr, Sheth N. Boroojerdi B, et al. Among authors: tatla d. Parkinsonism Relat Disord. 2019 Apr;61:70-76. doi: 10.1016/j.parkreldis.2018.11.024. Epub 2018 Nov 27. Parkinsonism Relat Disord. 2019. PMID: 30635244
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.
Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, Heijde Dv, Vollenhoven Rv, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Emery P, et al. Among authors: tatla d. Ann Rheum Dis. 2016 Oct;75(10):e69. doi: 10.1136/annrheumdis-2016-210083. Epub 2016 Aug 12. Ann Rheum Dis. 2016. PMID: 27519773 Free article. No abstract available.
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Emery P, et al. Among authors: tatla d. Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10. Ann Rheum Dis. 2017. PMID: 27165179 Free PMC article. Clinical Trial.
Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial.
Hohnloser SH, Al-Khalidi HR, Pratt CM, Brum JM, Tatla DS, Tchou P, Dorian P; SHock Inhibition Evaluation with AzimiLiDe (SHIELD) Investigators. Hohnloser SH, et al. Among authors: tatla ds. Eur Heart J. 2006 Dec;27(24):3027-32. doi: 10.1093/eurheartj/ehl276. Epub 2006 Oct 18. Eur Heart J. 2006. PMID: 17050586 Clinical Trial.
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM; SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Dorian P, et al. Among authors: tatla ds. Circulation. 2004 Dec 14;110(24):3646-54. doi: 10.1161/01.CIR.0000149240.98971.A8. Epub 2004 Nov 8. Circulation. 2004. PMID: 15533855 Clinical Trial.
Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator.
Pratt CM, Dorian P, Al-Khalidi HR, Brum JM, Borggrefe M, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, Holroyde MJ, van der Laan M, Hohnloser SH; SHIELD Investigators. Pratt CM, et al. Among authors: tatla ds. Am J Cardiol. 2005 Jan 15;95(2):274-6. doi: 10.1016/j.amjcard.2004.08.096. Am J Cardiol. 2005. PMID: 15642569